{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"100","value":"92.6"},{"groupId":"OG001","lowerLimit":"70.3","upperLimit":"100","value":"95.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"Adherence is the percentage of ideal number of pills taken while on study (based on returned diaries)","dispersionType":"Full Range","groups":[{"description":"Patients receive oral armodafinil once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity.\n\nArmodafinil: Given orally","id":"OG000","title":"Arm I - Armodafinil"},{"description":"Patients receive oral placebo once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity.\n\nplacebo: Given orally","id":"OG001","title":"Arm II - Placebo"}],"paramType":"MEAN","populationDescription":"Participants who returned pill diaries","reportingStatus":"POSTED","timeFrame":"4 weeks post-RT (approximately 3 months post randomization)","title":"Adherence","type":"PRIMARY","unitOfMeasure":"percentage of ideal number of pills"}